STERIS plc
STEBusiness Overview
ticker: STE step: 01 generated: 2026-05-13 source: quick-research
STERIS plc (STE) — Business Overview
Business Description
STERIS plc is a global leader in infection prevention, sterilization, and contamination control products and services for healthcare, life sciences, and medical device manufacturing. The company operates across three segments: Healthcare (sterile processing equipment + infection prevention consumables), Applied Sterilization Technologies (AST - contract sterilization services for medical device companies), and Life Sciences (contamination control for biopharmaceutical manufacturing). STERIS divested its Dental segment for $787.5M in early FY2025, sharpening focus on core segments. FY2025 (fiscal year ending March 2025) revenue was $5.5B, up 6% YoY.
Revenue Model
Revenue is split across services (~55%), consumables (~25%), and capital equipment (~20%). Services include contract sterilization (AST) and maintenance/repair on installed equipment — highly recurring and sticky. Consumables (sterile processing chemistries, surgical drapes, gowns) are high-frequency repeat purchases. Capital equipment (sterilizers, washers, surgical tables) is more lumpy but builds the installed base. The key dynamic: equipment placement leads to a long tail of recurring services and consumables revenue, creating a razor-and-blade business model.
Products & Services
- Sterilizers & Washers: Autoclaves, low-temperature sterilizers, endoscope reprocessors for hospital sterile processing departments
- Infection Prevention Consumables: Sterile drapes, gowns, instrument protection, reprocessing chemistries
- AST Contract Sterilization: Gamma, electron beam, EtO (ethylene oxide), X-ray sterilization for medical device manufacturers; STERIS is the global #1 in this market
- Life Sciences: Contamination control chemicals, washers, disinfection systems for biopharma manufacturing environments
- OR Integration / Surgical Tables: Surgical table systems, lighting, and equipment management
Customer Base & Go-to-Market
Healthcare segment: hospital sterile processing departments, operating rooms, endoscopy suites. AST segment: medical device OEMs (Medtronic, Stryker, BD) outsourcing sterilization of single-use devices. Life Sciences: biopharmaceutical manufacturers (Pfizer, Merck, J&J). High customer retention — once a hospital integrates STERIS systems and protocols, switching costs are high due to staff training, regulatory approvals, and process validation requirements.
Competitive Position
STERIS is the global #1 in contract medical device sterilization (AST) and a top-2 player in hospital sterile processing equipment (competing with Getinge and Belimed). The infection prevention/sterilization market has high barriers: regulatory approvals, capital intensity of sterilization facilities, specialized expertise, and long hospital procurement cycles. STERIS has expanded via acquisitions (Synergy Health, ISS, Key Surgical, Cantel Medical) and now has an unmatched global infrastructure with 50+ sterilization facilities across the Americas, Europe, and Asia.
Key Facts
- Founded: 1985 (as Innovative Medical Technologies); modern STERIS formed from multiple acquisitions
- Headquarters: Dublin, Ireland (incorporated); operations HQ in Mentor, Ohio
- Employees: ~20,000+
- Exchange: NYSE
- Sector / Industry: Health Care / Health Care Equipment
- Fiscal Year: Ends March 31
- Market Cap: ~$20–23B
Financial Snapshot
ticker: STE step: 04 generated: 2026-05-13 source: quick-research
STERIS plc (STE) — Financial Snapshot
Income Statement Summary (Fiscal Year ends March 31)
| Metric | FY2022 | FY2023 | FY2024 | YoY |
|---|---|---|---|---|
| Revenue | ~$4.23B | $4.54B | $5.14B | +13.3% |
| Gross Margin | ~45% | ~44% | ~44% | |
| Operating Margin | ~17% | ~16% | ~17% | |
| Net Income | ~$480M | ~$490M | ~$550M | +12% |
| EPS (adjusted) | ~$7.50 | ~$7.90 | ~$9.20 | +16% |
FY2024 revenue jump (+13.3%) reflects bolt-on acquisitions and organic growth. FY2025 (ending March 2025) revenue: $5.5B (+6% organic); dental divestiture ($787.5M proceeds) removed lower-margin segment. FY2025 adjusted EPS estimated ~$9.25+. Note: services revenue +13% in FY2025; consumables +6%; capital equipment -4%.
Cash Flow & Balance Sheet (FY2025)
| Metric | Value |
|---|---|
| Operating Cash Flow (FY2025) | $1.15B |
| Free Cash Flow (FY2025) | $787M (+27% YoY) |
| Free Cash Flow (FY2024) | $620M |
| Dental Segment Divestiture | $787.5M (completed early FY2025) |
| Share Buybacks (FY2025) | $350.6M completed |
| Tariff Headwind (FY2026 est.) | ~$45M pre-tax impact |
Key Ratios (approximate)
- P/E: ~28x (adjusted) | EV/EBITDA: ~18–20x | FCF Yield: ~3–4%
- Revenue Growth (FY2025): +6% organic | FCF Growth: +27% YoY
- Services as % of Revenue: ~55% (highest-quality, most recurring)
- Consumables Growth (FY2025): +6-7%
Growth Profile
STERIS is a compounding medical device/services platform with predictable mid-to-high single digit organic revenue growth. The business is recession-resistant — hospital sterilization is non-elective and procedure volumes grow with aging demographics. Revenue mix has shifted toward services (sticky, recurring) and away from lumpy capital equipment, improving revenue quality. The Dental divestiture in FY2025 improves EBITDA margin by removing a lower-margin segment. AST (contract sterilization for medical devices) benefits from outsourcing trends as medical device OEMs prefer to use specialized third-party facilities rather than build/maintain their own sterilization infrastructure.
Forward Estimates
- FY2026 guidance (ending March 2026): Revenue +6-7% (raised to +8-9% including FX benefits); adjusted EPS $9.90-10.15
- Analyst consensus FY2026 adj. EPS: ~$10.21 (+10.7% YoY)
- Analyst mean price target: $288.43 (~15% upside from ~$251)
- Consensus: 6 Strong Buy, 3 Hold (9 analysts covering)
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $STE.